Prism Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 29-06-2024
- Paid Up Capital ₹ 0.50 M
as on 29-06-2024
- Company Age 26 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.49 M
as on 29-06-2024
- Revenue 603.21%
(FY 2022)
- Profit 301.42%
(FY 2022)
- Ebitda 92.62%
(FY 2022)
- Net Worth 29.41%
(FY 2022)
- Total Assets -87.62%
(FY 2022)
About Prism Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹5.49 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nitin Dalvi, Pratap Chandarana, and Narendra Shah serve as directors at the Company.
- CIN/LLPIN
U85195MH1998PTC115329
- Company No.
115329
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Prism Diagnostics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Dalvi  | Director | 12-Jun-1998 | Current |
| Pratap Chandarana | Director | 15-Feb-2001 | Current |
| Narendra Shah | Director | 12-Jun-1998 | Current |
Financial Performance and Corporate Structure Insights of Prism Diagnostics.
Prism Diagnostics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 603.21% increase. The company also saw a substantial improvement in profitability, with a 301.42% increase in profit. The company's net worth Soared by an impressive increase of 29.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prism Diagnostics?
In 2018, Prism Diagnostics had a promoter holding of 49.80% and a public holding of 50.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pooja Diagnostic Centre Private Limited
Active
28 years 11 months Pratap Chandarana is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The North Canara G.S.B. Co.Op Bank Ltd. Creation Date: 19 Jun 2006 | ₹0.94 M | Satisfied |
The North Kanara Gsb; Co-Op Bank Ltd Creation Date: 02 Feb 2005 | ₹0.50 M | Satisfied |
The North Kanara Gsb; Co-Op Bank Ltd Creation Date: 17 May 2004 | ₹0.50 M | Satisfied |
How Many Employees Work at Prism Diagnostics?
Unlock and access historical data on people associated with Prism Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prism Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prism Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
